Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen’s Biggest Seller Enbrel Hit By Pricing Pressures, Competition

Executive Summary

Amgen signaled future declines in revenue for its top-selling product Enbrel during its third quarter conference call as payer pressure on drug pricing and competition mounts.

Advertisement

Related Content

Pharma Q1 Results Preview: Lilly, Biogen, Amgen, GSK & Roche
Novartis Chief: Good Things Come To Those Who Wait
Can New Drugs Meet Lilly’s Revenue Goals If Solanezumab Fails?
Coherus, In Ring As A Biosimilar Contender, Hopes To Smack Down Humira
Pfizer Sets Inflectra Launch Date; J&J Plans To Fight Back
Amgen's Kyprolis Miss In First-Line Myeloma Surprising, But Clinically Irrelevant
Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira
Novartis/Sandoz Biosimilar Erelzi OK'd; Covets Enbrel's US Sales
Amgen Plugs Away On Repatha, With Hope For New Monthly Product
1st U.S. Biosimilar Arrives: Zarxio Launches; Legal Saga Ongoing

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097560

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel